factual
Patent Office and FDA Don't Ask If Drugs Are Better
A core structural flaw is that neither agency asks whether a drug delivers value: the Patent and Trademark Office only asks whether something is different, not better, and the FDA (unlike some other countries) only asks whether a drug is safe and effective, not whether it is better or delivers much value—so no one in the US system asks the value question, distorting incentives.
factualpending
Speaker
Robin FeldmanEvidence Quote
“the FDA, when it approves, doesn't ask whether something is better or delivers much value. It just asks whether something is safe and effective. Nobody is asking that question in our system.”
Created: 6/13/2026, 12:12:41 AM
Your notes
Loading notes...